FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula Ie, which function as inhibitors of enzymatic activity of RET kinase (tunable during transfection), where each of HET, X1, X2, X3, X4, R0, R2 and R3 is defined in the claim. Present invention also relates to methods of producing said compounds, to pharmaceutical compositions containing them, and to use thereof in treating proliferative disorders, such as cancer, as well as other diseases or conditions involving RET kinase activity.
EFFECT: disclosed are heterocyclic compounds as RET kinase inhibitors.
31 cl, 10 tbl, 97 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORY COMPOUNDS | 2018 |
|
RU2760669C2 |
| SUBSTITUTED N-(1H-INDAZOLE-4-YL) IMIDAZOLE [1,2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE TYPE III RECEPTOR | 2011 |
|
RU2591195C2 |
| SUBSTITUTED COMPOUNDS OF PYRAZOLE[1,5-a]PYRIMIDINE AS TRK KINASE INHIBITORS | 2010 |
|
RU2584157C2 |
| PYRAZOLOPYRIMIDINES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1993 |
|
RU2124016C1 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| NOVEL INDOLYSIN COMPOUNDS, METHOD FOR PRODUCING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2014 |
|
RU2693629C2 |
| SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TROPOMYOSIN-RELATED KINASE INHIBITORS | 2009 |
|
RU2523544C2 |
| PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | 2012 |
|
RU2606131C2 |
| BENZOYLAMINOHETEROCYCLYL COUMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | 2007 |
|
RU2440992C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
